DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. (DMAC) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · DMAC · as of Jun 8, 2026
Activity summary
Buy transactions
5
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
DiaMedica Therapeutics Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
DMAC insider buying and selling by quarter
DMAC insider selling · DMAC insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · DMAC ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
DMAC executive sell shares · DMAC board member insider trading · DMAC insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jan 2, 2026 | Parsons James T. Director | Award | 10,095 | $85K | Form 4 |
| Jan 2, 2026 | Giuffre Randall Michael Director | Award | 6,175 | $52K | Form 4 |
| Jan 2, 2026 | Semba Charles Pauling Director | Award | 3,355 | $28K | Form 4 |
| Nov 21, 2025 | Parsons James T. Director | Option | 12,000 | $26K | Form 4 |
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About DMAC insider trading
DMAC insider trades
DiaMedica Therapeutics Inc. (DMAC) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Parsons James T. (Director), Giuffre Randall Michael (Director), Semba Charles Pauling (Director). Over the past 12 months, 3 insiders have filed transactions with the SEC. DMAC insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For DiaMedica Therapeutics Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
DMAC insider trading · 5 questionsThe insiders of DiaMedica Therapeutics Inc. (DMAC) include executives and directors such as Parsons James T. (Director), Giuffre Randall Michael (Director), Semba Charles Pauling (Director), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026